VRNA

Verona Pharma plc (VRNA) 10Y Growth Potential Analysis (2026)

Invetso Score: 4/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Growth Durability

Gross margin remains very high at 95.5%, supporting strong unit economics.

Revenue base is still small relative to valuation, with price-to-sales at 541.7x and EV/sales at 540.3x.

No fresh news or metric change indicates a new growth catalyst this month.

Profitability

Operating profitability is still thin, with EBIT margin at 2.5% and operating margin at 1.3%.

Net margin remains negative at -2.9%, and ROE is -1.6%.

Interest coverage is only 0.10x, indicating limited earnings cushion.

Financial Strength

Liquidity remains very strong, with a current ratio of 10.7x and cash ratio of 8.5x.

Net debt remains negative relative to EBITDA, indicating a net cash position.

Debt-to-equity is 0.88x, but coverage ratios remain weak.

Valuation

Valuation remains extremely stretched, with EV/sales at 540.3x and price-to-free-cash-flow at 3,936.1x.

Price-to-book is 32.9x, leaving little margin for error.

No material news or metric improvement offsets the premium valuation.

Momentum

No recent news was provided to indicate a momentum shift.

The company still shows positive operating cash flow and free cash flow, but profitability remains weak.

Without fresh catalysts, momentum remains neutral to modest.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Verona Pharma plc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →